1. Impact of the COVID-19 Outbreak on the Management of Patients with Cancer

   • Eric Raymond
   • Catherine Thieblemont
   • Sandrine Faivre

   Review Article Open access 22 May 2020 Pages: 249 - 259

   

2. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

   • Margherita Ratti
   • Andrea Lampis
   • Jens C. Hahne

   Review Article Open access 25 May 2020 Pages: 261 - 278

   

3. Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

   • Aye Myat Thi
   • Sandar Tin Tin
   • J. Mark Elwood

   Systematic Review 22 May 2020 Pages: 279 - 299

   

4. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

   • Simon Chowdhury
   • Anders Bjartell
   • Luis Costa

   Original Research Article Open access 04 June 2020 Pages: 301 - 315

   

5. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy

   • Takanobu Yamada
   • Tsutomu Hayashi
   • Takashi Oshima

   Original Research Article 21 April 2020 Pages: 317 - 325

   

6. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors

   • Vincenzo Formica
   • Cristina Morelli
   • Hendrik-Tobias Arkenau

   Original Research Article 24 May 2020 Pages: 327 - 336

   

7. Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

   • Ya Chen
   • Shuyuan Wang
   • Baohui Han

   Original Research Article 03 June 2020 Pages: 337 - 345

   

8. Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

   • Kosuke Takemura
   • Takeshi Yuasa
   • Junji Yonese

   Original Research Article 30 May 2020 Pages: 347 - 356

   

9. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations

   • Haiyan Xu
   • Weihua Li
   • Yan Wang

   Original Research Article 16 May 2020 Pages: 357 - 364

   

10. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas

    • Shengnan Ding
    • Xia Mao
    • Jianfeng Zhou

    Original Research Article 03 June 2020 Pages: 365 - 375

    

11. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer

    • Jörg Hänze
    • Moritz Wegner
    • Axel Hegele

    Original Research Article Open access 03 June 2020 Pages: 377 - 390

    

12. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance

    • Domenica Lorusso
    • Jesús García-Donas
    • Florence Joly

    Therapy in Practice Open access 03 June 2020 Pages: 391 - 406

    

13. Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review

    • An-Katrien Seghers
    • Pieter-Jan Cuyle
    • Eric Van Cutsem

    Therapy in Practice 03 June 2020 Pages: 407 - 410

    

14. Comment on: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”

    • Yusuf Ziya Şener

    Letter to the Editor 27 May 2020 Pages: 411 - 411

15. Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”

    • Jwa Hoon Kim
    • Jeong Eun Kim
    • Yong Sang Hong

    Letter to the Editor 27 May 2020 Pages: 413 - 414